A hybrid molecular simulation/machine-learning framework for rapid and accurate computation of absolute binding free energies of lead-like molecules
A hybrid molecular simulation/machine-learning framework for rapid and accurate computation of absolute binding free energies of lead-like molecules
批准号:
2581380
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2021
资助国家:
英国
项目状态:
未结题
起止时间:
2021 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Free Energy Perturbation (FEP) methods are increasingly used to guide in silico potency optimisation of preclinical candidate compounds. FEP is most commonly used in the context of Relative Binding Free Energy (RBFE) calculations that are well suited to hit-to-lead or lead optimisation stages of a drug discovery campaign. However, RBFE methods are limited to the calculation of differences in binding affinity between structurally related molecules. It is highly desirable to develop methodologies that achieve accuracy comparable to RBFE but are applicable to a broader class of drug design problems. Examples of high value problems outside the scope of RBFE include: prediction of binding modes; ranking of diverse chemotypes; prediction of binding selectivity profiles. Such problems can in principle be tackled using Absolute Binding Free Energy (ABFE) calculation methods. However ABFE are currently considered too computationally intensive and unreliable to be widely used.This project will leverage preliminary results from the Michel lab to substantially increase the efficiency of ABFE calculations. In collaboration with the Cole lab, new simulation protocols that combine GPU-accelerated molecular dynamics simulations with machine learning of forcefields and sampling algorithms will be devised. The protocols will be benchmarked on diverse protein-ligand datasets of interest to AstraZeneca. The overall aim is to make ABFE calculations sufficiently rapid and accurate to enable routine use in industrial R&D. This is an exciting opportunity to develop next-generation computer-aided drug design software and methodologies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
配子生成素GGN不同位点突变损伤分子伴侣BIP及HSP90B1功能导致精子形成障碍的发病机理
-
批准号:82371616
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:姚晨成
-
依托单位:
MYRF/SLC7A11调控施万细胞铁死亡在三叉神经痛脱髓鞘病变中的作用和分子机制研究
-
批准号:82370981
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:陈敏洁
-
依托单位:
PET/MR多模态分子影像在阿尔茨海默病炎症机制中的研究
-
批准号:82372073
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:张淼
-
依托单位:
GREB1突变介导雌激素受体信号通路导致深部浸润型子宫内膜异位症的分子遗传机制研究
-
批准号:82371652
-
项目类别:面上项目
-
资助金额:45.00万元
-
批准年份:2023
-
负责人:刘开江
-
依托单位:
靶向PARylation介导的DNA损伤修复途径在恶性肿瘤治疗中的作用与分子机制研究
-
批准号:82373145
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:历鹏
-
依托单位:
OBSL1功能缺失导致多指(趾)畸形的分子机制及其临床诊断价值
-
批准号:82372328
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:项盈
-
依托单位:
O6-methyl-dGTP抑制胶质母细胞瘤的作用及分子机制研究
-
批准号:82304565
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:李瑾
-
依托单位:
转录因子LEF1低表达抑制HMGB1致子宫腺肌病患者子宫内膜容受性低下的分子机制
-
批准号:82371704
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:徐步芳
-
依托单位:
Irisin通过整合素调控黄河鲤肌纤维发育的分子机制研究
-
批准号:32303019
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:职韶阳
-
依托单位:
上皮细胞黏着结构半桥粒在热激保护中的作用机制研究
-
批准号:31900545
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2019
-
负责人:傅容
-
依托单位: